New weight loss drug WVE-007 enters early human testing

NCT ID NCT06842186

First seen Nov 18, 2025 · Last updated May 03, 2026 · Updated 22 times

Summary

This early-stage study is testing a new drug called WVE-007 in 136 adults with overweight or obesity (BMI 28-35). The main goal is to check if the drug is safe and how the body handles it. Participants will receive either the drug or a placebo as a single injection, and researchers will monitor side effects and drug levels in the blood.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY AND OVERWEIGHT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • ARENSIA Research Clinic

    RECRUITING

    Chisinau, MD-2025, Moldova

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Arensia Clinics S.R.L.

    RECRUITING

    Bucharest, 011658, Romania

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Parexel International Early Phase Clinical Unit

    RECRUITING

    Harrow, HA1 3UJ, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Parexel International-EPCU Baltimore

    RECRUITING

    Baltimore, Maryland, 21225, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Simbec-Orion Clinical Pharmacology

    RECRUITING

    Merthyr Tydfil, CF48 4DR, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Spitalul Clinic Judetean De Urgenta Cluj

    RECRUITING

    Cluj-Napoca, 400006, Romania

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.